Skip to main content

Trulicity News

FDA Medwatch Alert: Drug Safety Communication: Certain Type of Medicines Approved for Type 2 Diabetes and Obesity - Update on FDA’s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions

ISSUE: The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with a class of medicines called glucagon-like peptide-1 receptor agonists (GLP-1 RAs; see the list in...

Dulaglutide Cuts Weight Gain After Smoking Cessation

FRIDAY, Dec. 22, 2023 – Dulaglutide cuts post-smoking cessation weight gain in men and women, according to a study published online Dec. 19 in BMJ Nutrition, Prevention & Health. Fabienne Baur, ...

Racial, Ethnic Differences Seen for Benefits of Antihyperglycemic Agents

THURSDAY, Sept. 28, 2023 – There are racial/ethnic differences in the cardiorenal effects of sodium-glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1 receptor agonists...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Cardiovascular Risk Reduction, Diabetes, Type 2

Trulicity patient information at Drugs.com